Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2057 (LINC02057)
- Target
- LINC02057
- Molecular classification
- Long non-coding RNA (lncRNA), More specifically, long intergenic non-protein coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 2057 (LINC02057) is a human long non-coding RNA (lncRNA), specifically classified as a long intergenic non-protein coding RNA (lincRNA), encoded in the human genome on chromosome 5[3][1][9]. It does not code for a protein but is transcribed as a long RNA molecule over 200 nucleotides in length. Although little is known about the specific biological function of LINC02057, it has been identified as part of prognostic lncRNA signatures in esophageal squamous cell carcinoma (ESCC), where its expression is upregulated and may serve as a predictive biomarker for patient outcome and therapeutic response[2]. This molecule is not currently considered a classical therapeutic target (such as a receptor, enzyme, or transporter). It serves as a molecular biomarker, and more research is needed to elucidate its precise functional roles in disease and physiology[2][7][3].
- Other names
- LINC02057CTC-436P18.3LINC02057.1
02
Mechanism of action
Not applicable; no drugs target this RNA.
03
Biological functions
Putative regulation of gene expression at the RNA levelMay be involved with mRNA splicing, non-coding RNA processing, DNA damage repair response (as part of m5C-lncRNA prognostic signatures in esophageal squamous cell carcinoma)The broader class of lincRNAs is known to participate in various gene regulatory processes, though specific functions of LINC02057 are not well characterized
04
Disease associations
Cancer (specifically, implicated as part of an lncRNA prognostic signature for esophageal squamous cell carcinoma, ESCC)Reported overexpression in ESCC tissue and cell linesPotential association with other diseases is currently unreported in the literature. GWAS data are available but show no direct Mendelian disease associations
05
Safety considerations
Not reported.As LINC02057 is not a direct therapeutic target and no drugs act upon it, no specific safety or therapeutic concerns have been described
06
Interacting drugs
None known or reported in the literature as of now.
1 more in the full profile.
07
Biomarkers
Included in m5C-related long non-coding RNA prognostic signatures for ESCC, with suggested utility for patient stratification and therapeutic response prediction in esophageal cancerIts expression level may be considered as a prognostic biomarker in ESCC
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2057 (LINC02057).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2057 (LINC02057).